Isoxazoline-substituted benzamide compound and application thereof

MYPI2025001968A0Undetermined Publication Date: 2024-04-01QINGDAO KINGAGROOT CHEM COMPOUNDS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001968
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-29
Filing Date
2023-01-04
Publication Date
2024-04-01

AI Technical Summary

Technical Problem

Existing biological control agents have high toxicity and residual problems, making it difficult to effectively control pests. In addition, pest resistance has increased, resulting in the weakening of the effectiveness of traditional pesticides.

Method used

Develop an isoxazoline-substituted benzamide compound and its stereoisomers and salts for use in compounds with excellent control effects on a variety of pests such as Spodoptera Frugiperda, Spodoptera exigua, peanut aphid, etc., through specific Chemical structure and steric purity enhance its insecticidal properties.

Benefits of technology

The compound has high-efficiency control effects on a variety of pests, has low toxicity and low residue, can effectively deal with the problem of pest resistance, and provides a low-toxicity and low-residue biological control agent solution.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides an isoxazoline-substituted benzamide compound, a stereoisomer and an agriculturally or veterinarily acceptable salt thereof. The compound is as shown in Formula I: wherein, X represents hydrogen, halogen, alkoxy or alkylthio; Y represents halogen or haloalkyl; Z and Z1 each independently represent hydrogen, halogen, etc.; P and P1 each independently represent CH or N; Q and Q1 each independently represent alkyl, etc.; M represents hydrogen, alkyl, etc.; R represents hydrogen, alkyl, etc. The compound has excellent control effects on pest insects such as fall armyworm (Spodoptera frugiperda), beet armyworm (Spodoptera exigua), groundnut aphid (Aphis craccivora), two-spotted spider mite (Tetranychus urticae), striped rice stem borer (Chilo suppressalis), cotton aphid (Aphis gossypii), etc.
Need to check novelty before this filing date? Find Prior Art

Description

Isoxazoline-substituted benzamide compounds and their applications Technical Field

[0001] The invention belongs to the technical field of pesticides, and particularly relates to an isoxazoline-substituted benzamide compound and application thereof. Background Art

[0002] In recent years, due to the long-term use of pest control agents, such as insecticides or fungicides, pests and diseases have acquired drug resistance, making it difficult to control them with existing insecticides or fungicides. In addition, some known pest control agents are highly toxic, or some damage ecosystems through their long-term residual properties. In this situation, despite the existence of a large number of known pesticides, such as WO2015 / 128358, which discloses oxazoline compounds and their use as pesticides, there is still a need to develop new pest control agents with low toxicity and low residual properties.

[0003] Summary of the Invention

[0004] In order to solve the above-mentioned problems existing in the prior art, the present invention provides an isoxazoline-substituted benzamide compound, its stereoisomers and agriculturally or veterinarily acceptable salts, which have excellent control effects on pests such as fall armyworm, beet armyworm, peanut aphid, two-spotted spider mite, striped stem borer, cotton aphid, etc.

[0005] The technical solution adopted in the present invention is as follows:

[0006] An isoxazoline-substituted benzamide compound as shown in formula I, its stereoisomers and agriculturally or veterinarily acceptable salts:

[0007]

[0008] wherein X represents hydrogen, halogen, alkoxy or alkylthio;

[0009] Y represents halogen or halogenated alkyl;

[0010] Z, Z1 each independently represent hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl or cyano;

[0011] P and P1 independently represent CH or N;

[0012] Q and Q1 independently represent hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, cyanoalkyl, hydroxyalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkylthio, alkylamino, haloalkoxy, haloalkylthio, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, haloalkoxyalkyl, alkylaminoalkyl, aryl, heterocyclyl, arylalkyl or heterocyclylalkyl, wherein the "alkyl", "alkenyl" or "alkynyl" independently represent unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(CO)N(R1)2, -(SO2)R1 or -N(R1)2. wherein the “cycloalkyl”, “cycloalkylalkyl”, “aryl”, “heterocyclyl”, “arylalkyl” or “heterocyclylalkyl” are independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0013] M represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic, aryl, Wherein, the "alkyl", "alkenyl" or "alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, cycloalkyl, trialkylsilyl, cycloalkenyl, heterocyclic, aryl, wherein the “cycloalkyl”, “cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0014] R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic, aryl, Wherein, the "alkyl", "alkenyl" or "alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, cycloalkyl, trialkylsilyl, cycloalkenyl, heterocyclic, aryl, wherein the “cycloalkyl”, “cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0015] X 11 Each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, aryl or arylalkyl groups is independently represented by hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, aryl or arylalkyl, wherein the alkyl, alkenyl or alkynyl groups are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, aryl or arylalkyl groups are independently represented by hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, aryl or arylalkyl groups. " or "arylalkyl" are each independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0016] X 12Each independently represents an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylalkyl group, a cycloalkenyl group, a cycloalkenylalkyl group, a heterocyclyl group, a heterocyclylalkyl group, an aryl group or an arylalkyl group, wherein the "alkyl group", "alkenyl group" or "alkynyl group" are independently unsubstituted or substituted by at least one group selected from halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, The “cycloalkyl”, “cycloalkylalkyl”, “cycloalkenyl”, “cycloalkenylalkyl”, “heterocyclyl”, “heterocyclylalkyl”, “aryl” or “arylalkyl” are each independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0017] X 13 、X 14 Each independently represents hydrogen, halogen, cyano, alkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, or a group CX 13 X 14 Together they form an unsubstituted or substituted ring structure, or the group NX 13 X 14 Together they form an unsubstituted or substituted heterocyclic group with a nitrogen atom at the 1-position, wherein the "alkyl", "alkenyl" or "alkynyl" are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the "cycloalkyl", "cycloalkylalkyl", "cycloalkenyl", "cycloalkenylalkyl", "aryl", "arylalkyl", "heterocyclyl" or "heterocyclylalkyl" are independently unsubstituted. or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0018] R1 independently represents hydrogen, alkyl, haloalkyl, phenyl or phenyl substituted by at least one group selected from halogen, cyano, nitro, alkyl, haloalkyl, alkoxycarbonyl, alkylthio, alkylsulfonyl, alkoxy or haloalkoxy.

[0019] Preferably, X represents hydrogen, halogen, C1-C8 alkoxy or C1-C8 alkylthio;

[0020] Y represents halogen or halogenated C1-C8 alkyl;

[0021] Z and Z1 independently represent hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halogenated C1-C8 alkyl or cyano;

[0022] Q and Q1 independently represent hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, cyano C1-C8 alkyl, hydroxy C1-C8 alkyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, C1-C8 alkylamino, halogenated C1-C8 alkoxy, halogenated C1-C8 alkylthio, C1-C8 alkylcarbonyl, C1-C8 C1-C8 alkoxycarbonyl, C1-C8 alkoxy C1-C8 alkyl, halogenated C1-C8 alkoxy C1-C8 alkyl, C1-C8 alkylamino C1-C8 alkyl, aryl, heterocyclic, aryl C1-C8 alkyl or heterocyclic C1-C8 alkyl, wherein the "C1-C8 alkyl", "C2-C8 alkenyl" or "C2-C8 alkynyl" are each independently unsubstituted or substituted by halogen, -OR1, -SR1, -(CO)OR1, -(CO)N(R1)2 , -(SO2)R1 or -N(R1)2, wherein the "C3-C8 cycloalkyl", "C3-C8 cycloalkyl C1-C8 alkyl", "aryl", "heterocyclyl", "aryl C1-C8 alkyl" or "heterocyclyl C1-C8 alkyl" are independently unsubstituted or selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halogenated C1-C8 alkyl, substituted by at least one of a halogenated C2-C8 alkenyl group, a halogenated C2-C8 alkynyl group, a halogenated C3-C8 cycloalkyl group, a C3-C8 cycloalkyl group substituted by a C1-C8 alkyl group, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2, or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a condensed ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0023] M represents hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, heterocyclic group, aryl, Wherein, the "C1-C8 alkyl", "C2-C8 alkenyl" or "C2-C8 alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, C3-C8 cycloalkyl, tri-C1-C8 alkylsilyl, C3-C8 cycloalkenyl, heterocyclyl, aryl, wherein the “C3-C8 cycloalkyl”, “C3-C8 cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo-C1-C8 alkyl, halo-C2-C8 alkenyl, halo-C2-C8 alkynyl, halo-C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by C1-C8 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0024] R represents hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, heterocyclic group, aryl, Wherein, the "C1-C8 alkyl", "C2-C8 alkenyl" or "C2-C8 alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, C3-C8 cycloalkyl, tri-C1-C8 alkylsilyl, C3-C8 cycloalkenyl, heterocyclyl, aryl, wherein the “C3-C8 cycloalkyl”, “C3-C8 cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo-C1-C8 alkyl, halo-C2-C8 alkenyl, halo-C2-C8 alkynyl, halo-C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by C1-C8 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0025] X 11 Each of the "C1-C8 alkyl", "C2-C8 alkenyl" and "C2-C8 alkynyl" independently represents hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C8 alkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkenylC1-C8 alkyl, heterocyclyl, heterocyclylC1-C8 alkyl, aryl or arylC1-C8 alkyl, wherein the "C1-C8 alkyl", "C2-C8 alkenyl" or "C2-C8 alkynyl" are independently unsubstituted or replaced by halogen, -OR1, -SR1, -(CO)OR1, -( SO2)R1 or -N(R1)2, the "C3-C8 cycloalkyl", "C3-C8 cycloalkyl C1-C8 alkyl", "C3-C8 cycloalkenyl", "C3-C8 cycloalkenyl C1-C8 alkyl", "heterocyclyl", "heterocyclyl C1-C8 alkyl", "aryl" or "aryl C1-C8 alkyl" are independently unsubstituted or selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, substituted by at least one of halogenated C1-C8 alkyl, halogenated C2-C8 alkenyl, halogenated C2-C8 alkynyl, halogenated C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by C1-C8 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2, or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a condensed ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0026] X 12and C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C8 alkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkenylC1-C8 alkyl, heterocyclyl, heterocyclylC1-C8 alkyl, aryl or arylC1-C8 alkyl, wherein the “C1-C8 alkyl”, “C2-C8 alkenyl” or “C2-C8 alkynyl” are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the “C3-C8 cycloalkyl”, “C3-C8 cycloalkylC1-C8 alkyl”, “C3-C8 cycloalkenyl”, “C3-C8 cycloalkenylC1-C8 alkyl”, “heterocyclylC1-C8 alkyl”, "Cycyl", "heterocyclyl C1-C8 alkyl", "aryl" or "aryl C1-C8 alkyl" are each independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo-C1-C8 alkyl, halo-C2-C8 alkenyl, halo-C2-C8 alkynyl, halo-C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by C1-C8 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0027] X 13 、X 14 Each independently represents hydrogen, halogen, cyano, C1-C8 alkoxy, C1-C8 alkoxyC1-C8 alkyl, C1-C8 alkylcarbonyl, C1-C8 alkoxycarbonyl, C1-C8 alkylsulfonyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C8 alkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkenylC1-C8 alkyl, aryl, arylC1-C8 alkyl, heterocyclyl or heterocyclylC1-C8 alkyl, or the group CX 13 X 14 Together they form a 5- to 8-membered carbon ring or a heterocyclic ring containing oxygen, sulfur or nitrogen, or the group NX 13 X 14 Together wherein the “C1-C8 alkyl”, “C2-C8 alkenyl” or “C2-C8 alkynyl” are each independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2; and the “C3-C8 cycloalkyl”, “C3-C8 cycloalkylC1-C8 alkyl”, “C3-C8 cycloalkenyl”, “C3-C8 cycloalkenylC1-C8 alkyl”, “aryl”, “arylC1-C8 alkyl”, “heterocyclyl” or “heterocyclylC1-C8 alkyl” are each independently unsubstituted or substituted by at least one of oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo The 5- to 8-membered carbon ring or heterocyclic ring containing oxygen, sulfur or nitrogen is unsubstituted or substituted by at least one group selected from C1-C8 alkyl, C1-C8 alkoxycarbonyl or benzyl, or forms a condensed ring structure with aryl or heterocyclic group; is unsubstituted or substituted by at least one group selected from oxo, C1-C8 alkyl or C1-C8 alkoxycarbonyl;

[0028] R1 independently represents hydrogen, C1-C8 alkyl, halogenated C1-C8 alkyl, phenyl or phenyl substituted by at least one group selected from halogen, cyano, nitro, C1-C8 alkyl, halogenated C1-C8 alkyl, C1-C8 alkoxycarbonyl, C1-C8 alkylthio, C1-C8 alkylsulfonyl, C1-C8 alkoxy or halogenated C1-C8 alkoxy.

[0029] More preferably, X represents hydrogen, halogen, C1-C6 alkoxy or C1-C6 alkylthio;

[0030] Y represents halogen or halogenated C1-C6 alkyl;

[0031] Z and Z1 independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halogenated C1-C6 alkyl or cyano;

[0032] Q and Q1 each independently represent hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, cyano C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, halogenated C1-C6 alkoxy, halogenated C1-C6 alkylthio, C1-C6 alkylcarbonyl, C1-C C1-C6 alkoxycarbonyl, C1-C6 alkoxy C1-C6 alkyl, halogenated C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkylamino C1-C6 alkyl, aryl, heterocyclic, aryl C1-C6 alkyl or heterocyclic C1-C6 alkyl, wherein the "C1-C6 alkyl", "C2-C6 alkenyl" or "C2-C6 alkynyl" are each independently unsubstituted or substituted by halogen, -OR1, -SR1, -(CO)OR1, -(CO)N(R1)2 , -(SO2)R1 or -N(R1)2, wherein the "C3-C6 cycloalkyl", "C3-C6 cycloalkyl C1-C6 alkyl", "aryl", "heterocyclyl", "aryl C1-C6 alkyl" or "heterocyclyl C1-C6 alkyl" are independently unsubstituted or selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halogenated C1-C6 alkyl, substituted by at least one of a halogenated C2-C6 alkenyl, a halogenated C2-C6 alkynyl, a halogenated C3-C6 cycloalkyl, a C3-C6 cycloalkyl substituted by a C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2, or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a condensed ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0033] M represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, heterocyclic group, aryl, Wherein, the "C1-C6 alkyl", "C2-C6 alkenyl" or "C2-C6 alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, C3-C6 cycloalkyl, tri-C1-C6 alkylsilyl, C3-C6 cycloalkenyl, heterocyclyl, aryl, wherein the “C3-C6 cycloalkyl”, “C3-C6 cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo-C1-C6 alkyl, halo-C2-C6 alkenyl, halo-C2-C6 alkynyl, halo-C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted by C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0034] R represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, heterocyclic group, aryl, Wherein, the "C1-C6 alkyl", "C2-C6 alkenyl" or "C2-C6 alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, C3-C6 cycloalkyl, tri-C1-C6 alkylsilyl, C3-C6 cycloalkenyl, heterocyclyl, aryl, wherein the “C3-C6 cycloalkyl”, “C3-C6 cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo-C1-C6 alkyl, halo-C2-C6 alkenyl, halo-C2-C6 alkynyl, halo-C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted by C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0035] X 11and C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C6 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylC1-C6 alkyl, heterocyclyl, heterocyclylC1-C6 alkyl, aryl or arylC1-C6 alkyl, wherein the “C1-C6 alkyl”, “C2-C6 alkenyl” or “C2-C6 alkynyl” are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the “C3-C6 cycloalkyl”, “C3-C6 cycloalkylC1-C6 alkyl”, “C3-C6 cycloalkenyl”, “C3-C6 cycloalkenylC1-C6 alkyl”, "heterocyclyl", "heterocyclyl C1-C6 alkyl", "aryl" or "aryl C1-C6 alkyl" are each independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo-C1-C6 alkyl, halo-C2-C6 alkenyl, halo-C2-C6 alkynyl, halo-C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted by C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0036] X 12and C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C6 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylC1-C6 alkyl, heterocyclyl, heterocyclylC1-C6 alkyl, aryl or arylC1-C6 alkyl, wherein the “C1-C6 alkyl”, “C2-C6 alkenyl” or “C2-C6 alkynyl” are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the “C3-C6 cycloalkyl”, “C3-C6 cycloalkylC1-C6 alkyl”, “C3-C6 cycloalkenyl”, “C3-C6 cycloalkenylC1-C6 alkyl”, “heterocyclylC1-C6 alkyl”, "Cycyl", "heterocyclyl C1-C6 alkyl", "aryl" or "aryl C1-C6 alkyl" are each independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo-C1-C6 alkyl, halo-C2-C6 alkenyl, halo-C2-C6 alkynyl, halo-C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted by C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-;

[0037] X 13 、X 14 Each independently represents hydrogen, halogen, cyano, C1-C6 alkoxy, C1-C6 alkoxyC1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfonyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C6 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylC1-C6 alkyl, aryl, arylC1-C6 alkyl, heterocyclyl or heterocyclylC1-C6 alkyl, or the group CX 13 X 14 Together they form a 5- to 8-membered carbon ring or a heterocyclic ring containing oxygen, sulfur or nitrogen, or the group NX 13 X 14 Together wherein the “C1-C6 alkyl”, “C2-C6 alkenyl” or “C2-C6 alkynyl” are each independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2; and the “C3-C6 cycloalkyl”, “C3-C6 cycloalkylC1-C6 alkyl”, “C3-C6 cycloalkenyl”, “C3-C6 cycloalkenylC1-C6 alkyl”, “aryl”, “arylC1-C6 alkyl”, “heterocyclyl” or “heterocyclylC1-C6 alkyl” are each independently unsubstituted or substituted by at least one of oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo The 5- to 8-membered carbon ring or heterocyclic ring containing oxygen, sulfur or nitrogen is unsubstituted or substituted by at least one of C1-C6 alkyl, C1-C6 alkoxycarbonyl or benzyl, or forms a condensed ring structure with aryl or heterocyclic group; is unsubstituted or substituted by at least one group selected from oxo, C1-C6 alkyl or C1-C6 alkoxycarbonyl;

[0038] R1 independently represents hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, phenyl or phenyl substituted by at least one group selected from halogen, cyano, nitro, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxycarbonyl, C1-C6 alkylthio, C1-C6 alkylsulfonyl, C1-C6 alkoxy or halogenated C1-C6 alkoxy.

[0039] In one embodiment, X represents hydrogen, fluorine, chlorine, methoxy or methylthio;

[0040] Y represents chlorine or fluorine;

[0041] Z represents hydrogen, methyl, ethyl, isopropyl, chlorine, trifluoromethyl or vinyl;

[0042] Z1 represents hydrogen or chlorine;

[0043] Q represents hydrogen, methyl, isopropyl, cyclopropyl, methoxy, trifluoromethyl, benzyl,

[0044] Q1 represents hydrogen;

[0045] P stands for CH or N;

[0046] P1 represents CH or N;

[0047] M represents hydrogen, methyl, ethyl, allyl, propargyl,

[0048] R represents hydrogen or methyl.

[0049] In another embodiment, P and P1 are not N at the same time.

[0050] In another embodiment, P represents CH, P1 represents CH, Q1 represents hydrogen, and Z1 represents hydrogen.

[0051] In another embodiment, P1 represents CH, Q1 represents hydrogen, and Z1 represents hydrogen.

[0052] In the definitions of the compounds represented by the above general formula and all the following structural formulas, the technical terms used, whether used alone or in compound terms, represent the following substituents: Alkyl groups having more than two carbon atoms can be straight-chain or branched. For example, in the compound term "-O-(alkyl)-COOR1," the alkyl group can be -CH2-, -CH2CH2-, -CH(CH3)-, -C(CH3)2-, etc. Alkyl groups include, for example, C1 alkyl-methyl; C2 alkyl-ethyl; C3 alkyl-propyl, such as n-propyl or isopropyl; C4 alkyl-butyl, such as n-butyl, isobutyl, tert-butyl, or 2-butyl; C5 alkyl-pentyl, such as n-pentyl; and C6 alkyl-hexyl, such as n-hexyl, isohexyl, and 1,3-dimethylbutyl. Similarly, alkenyl is, for example, vinyl, allyl, 1-methylprop-2-ene-1-yl, 2-methylprop-2-ene-1-yl, but-2-ene-1-yl, but-3-ene-1-yl, 1-methylbut-3-ene-1-yl and 1-methylbut-2-ene-1-yl. Alkynyl is, for example, ethynyl, propargyl, but-2-yn-1-yl, but-3-yn-1-yl, 1-methylbut-3-yn-1-yl. Multiple bonds can be at any position of each unsaturated group. Cycloalkyl is a carbocyclic saturated ring system with, for example, three to six carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Similarly, cycloalkenyl is a monocyclic alkenyl with, for example, three to six carbocyclic ring members, such as cyclopropenyl, cyclobutenyl, cyclopentenyl and cyclohexenyl, wherein double bonds can be at any position. Halogen is fluorine, chlorine, bromine or iodine.

[0053] Unless otherwise specified, the "aryl" mentioned in the present invention includes but is not limited to phenyl, naphthyl, The "heterocyclic group" includes but is not limited to saturated or unsaturated non-aromatic cyclic groups etc., and also include but are not limited to heteroaryl, i.e. an aromatic cyclic group containing, for example, 3 to 6 ring atoms and optionally fused to a benzo ring, wherein 1 to 4 (e.g. 1, 2, 3 or 4) heteroatoms in the ring atoms are selected from oxygen, nitrogen and sulfur, for example

[0054] If a group is substituted by a group, this is understood to mean that the group is substituted by one or more identical or different groups selected from the groups mentioned. Furthermore, identical or different substituent characters contained in identical or different substituents are independently selected and may be identical or different. The same applies to ring systems formed from different atoms and units. At the same time, compounds known to those skilled in the art to be chemically unstable under standard conditions are excluded from the scope of the claims.

[0055] In addition, unless otherwise specified, the term "substituted by at least one group" as used herein refers to being substituted by 1, 2, 3, 4 or 5 groups; groups (including heterocyclic groups, aryl groups, etc.) without a specific connection position can be connected at any position, including the position connected to C or N; if it is substituted, the substituent can also be substituted at any position as long as it complies with the chemical bond connection rules. For example, a heteroaryl group substituted by 1 methyl group Can represent wait.

[0056] The present invention provides an isoxazoline-substituted benzamide compound having a chiral center as shown in Formula I', its stereoisomers and agriculturally or veterinarily acceptable salts:

[0057]

[0058] wherein the substituents X, Y, Z, Z1, P, P1, R, Q, Q1, and M are as defined above, and Q and Q1 are different; the carbon atom at position 2 is a chiral center, and based on the content of stereoisomers having R and S configurations at this position, it has a stereochemical purity of 60-100% (R), preferably 70-100% (R), more preferably 80-100% (R), further preferably 90-100% (R), and even more preferably 95-100% (R).

[0059] The present invention also provides an isoxazoline-substituted benzamide compound having a chiral center as shown in Formula I", its stereoisomers and agriculturally or veterinarily acceptable salts:

[0060]

[0061] Wherein, the substituents X, Y, Z, Z1, P, P1, R, Q, Q1, and M are as defined above, and Q and Q1 are different;

[0062] Based on the content of stereoisomers having R and S configurations at position 5, it has a stereochemical purity of 60-100% (S), preferably 70-100% (S), more preferably 80-100% (S), further preferably 90-100% (S), and even more preferably 95-100% (S);

[0063] The carbon atom at position 2 is a chiral center. Based on the content of stereoisomers with R and S configurations at this position, it has a stereochemical purity of 60-100% (R), preferably 70-100% (R), more preferably 80-100% (R), further preferably 90-100% (R), and even more preferably 95-100% (R).

[0064] Here, "stereochemical purity" refers to the percentage of the amount of the stereoisomer in question to the total amount of stereoisomers having a chiral center.

[0065] In the present invention, the stereochemical configuration at positions 5 and 2 in Formula I' and Formula I" is determined to be predominantly (5S) and (2R), respectively, according to the Cahn-Ingold-Prelog system. However, the subject matter of the present invention also relates to all stereoisomers at other positions encompassed by Formula I, Formula I' and Formula I", and mixtures thereof. Such compounds of Formula I, Formula I' and Formula I" may contain, for example, one or more additional asymmetric carbon atoms or other double bonds not specifically described in Formula I, Formula I' and Formula I". It should be understood that the present invention includes pure isomers and mixtures thereof enriched to varying degrees in pure isomers, wherein the asymmetric carbon atom at the marked position 5 is in the S-configuration and / or the asymmetric carbon atom at the marked position 2 is in the R-configuration, or in mixtures in which compounds or compounds of the same chemical structure have the configurations at the marked positions, or are present in a proportion in which the compounds having the configurations are predominant (at least 60% of the configurations), while the other asymmetric carbon atoms may be present in racemic form or may be resolved to varying degrees. As long as the stereochemical configuration conditions at the marked positions are met, possible stereoisomers defined by specific spatial forms, such as enantiomers, diastereomers, Z- and E-isomers, are included in Formula I, Formula I' and Formula I", and can be obtained from mixtures of stereoisomers using conventional methods, or can be prepared by stereoselective reactions combined with the use of stereochemically pure starting materials.

[0066] If various functional groups are present, the present invention also includes any keto and enol tautomeric forms and mixtures and salts thereof.

[0067] Stereoisomers can be obtained from the mixture obtained in the preparation by optical resolution. Stereoisomers can also be selectively prepared by using stereoselective reactions and optically active starting materials and / or auxiliary agents. For optical resolution, conventional methods (see Textbooks of Stereochemistry) can usually be used, such as the following methods for separating the mixture into diastereomers, such as physical methods, such as crystallization, chromatography, especially column chromatography and high pressure liquid chromatography, optionally distillation methods under reduced pressure, extraction methods and other methods, usually using chromatographic separation on a chiral solid phase, which can separate the residual mixture of enantiomeric structures. Suitable for preparation or for industrial scale is such a method, such as crystallization of diastereomeric salts, which can be obtained from compounds using optically active acids, and if an acidic group is present, optically active bases can be used as needed.

[0068] The salts of the compounds of the formula I, formula I' and formula I" are preferably agriculturally and veterinarily acceptable salts. They can be formed in a customary manner, for example by reacting the compounds with acids of the anions mentioned, if the compounds of the formula I, formula I' and formula I" have basic functional groups, or by reacting acidic compounds of the formula I, formula I' and formula I" with suitable bases.

[0069] Suitable agriculturally acceptable salts are in particular salts of those cations or acid addition salts of those acids whose cations and anions, respectively, do not have any adverse effect on the action of the compounds according to the invention. Suitable cations are in particular alkali metal ions, preferably lithium, sodium and potassium ions; alkaline earth metal ions, preferably calcium, magnesium and barium ions; transition metal ions, preferably manganese, copper, zinc and iron ions; and ammonium (NH4 + ) and substituted ammonium in which 1 to 4 hydrogen atoms are replaced by C1-C4 alkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkoxy-C1-C4 alkyl, hydroxy-C1-C4 alkoxy-C1-C4 alkyl, phenyl or benzyl. Examples of substituted ammonium ions include methylammonium, isopropylammonium, dimethylammonium, diisopropylammonium, trimethylammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, 2-hydroxyethylammonium, 2-(2-hydroxyethoxy)ethylammonium, di(2-hydroxyethyl)ammonium, benzyltrimethylammonium and benzyltriethylammonium, in addition to ions, sulfonium ions, preferably tri(C1-C4 alkyl)sulfonium, and sulfoxide ions, preferably tri(C1-C4 alkyl)sulfoxide.

[0070] Anions of useful acid addition salts are primarily chloride, bromide, fluoride, hydrogensulfate, sulfate, dihydrogenphosphate, hydrogenphosphate, phosphate, nitrate, hydrogencarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate and anions of C1-C4-alkanoic acids, preferably formate, acetate, propionate and butyrate. They can be formed by reacting compounds of the formula I, formula I' and formula I" with an acid of the corresponding anion, preferably hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or nitric acid.

[0071] The term "veterinarily acceptable salt" refers to salts of those cations or anions that are known and accepted in the art of veterinary salt formation. Suitable acid addition salts formed, for example, with compounds of Formula I, Formula I' and Formula I" containing a basic nitrogen atom, such as an amino group, include salts with inorganic acids, such as hydrochlorides, sulfates, phosphates and nitrates, and organic acids, such as acetic acid, maleic acid, dimaleic acid, fumaric acid, difumaric acid, methanesulfenic acid, methanesulfonic acid and succinic acid.

[0072] The compounds of the present invention, including their salts, stereoisomers, and tautomers, are particularly suitable for effectively controlling invertebrate pests. "Invertebrate pests" include arthropods, gastropods, nematodes, and worms that are economically important pests. The term "arthropod" includes insects, mites, spiders, scorpions, centipedes, millipedes, woodlice, and synechids. The term "gastropod" includes snails, slugs, and other stylopods. The term "nematode" includes all members of the class Nematoda. It is particularly suitable for effectively controlling or eliminating the following pests: lepidoptera insects (Lepidoptera), beetles (Coleoptera), flies, mosquitoes (Diptera), thrips (Thysanoptera), termites (Isoptera), cockroaches (Blattaria-Blattodea), bed bugs, aphids, leafhoppers, whiteflies, scales, cicadas (Hemiptera), ants, bees, wasps, sawflies (Hymenoptera), era), crickets, grasshoppers, locusts (Orthoptera), arachnids (Arachnida), fleas (Siphonaptera), silverfish, house silverfish (Thysanura), centipedes (Chilopoda), millipedes (Diplopoda), earwigs (Dermaptera), lice (Phthiraptera), springtails (Collembola), etc. They may infest plants, thereby causing significant damage to the infested plants, and may infect animals, especially warm-blooded animals such as mammals or birds or other higher animals such as reptiles, amphibians or fish, thereby causing significant damage to the infested animals.

[0073] The present invention also relates to a method for preparing the isoxazoline-substituted benzamide compound, its stereoisomers and agriculturally or veterinarily acceptable salts, comprising the following steps:

[0074] The compound represented by general formula II is reacted with the compound represented by general formula III in the presence of a condensing agent to obtain a compound represented by general formula I. The chemical reaction equation is as follows:

[0075]

[0076] Wherein, the definitions of substituents X, Y, Z, Z1, P, P1, R, Q, Q1, and M are as described above.

[0077] Preferably, the condensing agent is PyBOP, HATU, HOBt-EDCI, CDI, DCC or DBU, etc.; and the reaction is carried out in the presence of a base and a solvent.

[0078] The solvent is selected from one or more mixed solvents of dichloromethane, dichloroethane, acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, tetrahydrofuran, toluene, and xylene; and the base is selected from one or more of triethylamine, trimethylamine, DIPEA, and NMM.

[0079] In one embodiment, the compound represented by general formula II is prepared by hydrolyzing the compound represented by general formula IV, and the chemical reaction equation is as follows:

[0080]

[0081] The compound represented by general formula IV is prepared by a cycloaddition reaction between the compound represented by general formula V and the compound represented by general formula VI. The chemical reaction equation is as follows:

[0082]

[0083] Wherein, Hal represents halogen, and W represents C1-C6 alkyl or phenyl.

[0084] In addition, the above-mentioned compound can be prepared by referring to the methods shown in CN111936492A, WO2005 / 085216, etc.

[0085] The present invention also relates to an insecticide composition comprising a biologically effective amount of the isoxazoline-substituted benzamide compound, at least one of its stereoisomers and agriculturally or veterinarily acceptable salts, and preferably, further comprising a formulation adjuvant.

[0086] Such compositions may comprise an individual active compound according to the invention or a mixture of several active compounds according to the invention.The compositions according to the invention may comprise individual isomers or mixtures of isomers or salts as well as individual tautomers or mixtures of tautomers.

[0087] In addition, the composition of the present invention may also include an insecticide or acaricide having an action mechanism classified according to IRAC regulations as an active ingredient, and the combined application has obvious synergistic and synergistic effects.

[0088] Examples of insecticides or acaricides having a mechanism of action classified according to the IRAC regulations include (1A) acetylcholinesterase (AChE) inhibitors (carbamate type), (1B) acetylcholinesterase (AChE) inhibitors (organophosphorus type), (2) GABA-activated chloride ion (chloride) channel blockers, (3A) sodium channel modulators (pyrethroid type), (3B) sodium channel modulators (DDT type), (4) nicotinic acetylcholine receptor (nACR) inhibitors, and (5) nicotinic acetylcholine receptor (nACR) inhibitors. hR) competitive modulators, (5) nicotinic acetylcholine receptor (nAChR) allosteric modulators, (6) glutamate-activated chloride ion (chloride) channel (GluCl) allosteric modulators, (7) juvenile hormone analogs, (8) other nonspecific (multi-site inhibitors, (9) chord organ TRPV channel modulators, (10) mite growth inhibitors, (11) microbial-derived insect midgut membrane disruptors, (12) mitochondrial ATP synthase inhibitors, ( 13) Oxidative phosphorylation uncouplers that disrupt the proton gradient, (14) Nicotinic acetylcholine receptor (nAChR) channel blockers, (15) Chitin biosynthesis inhibitors, type 0, (16) Chitin biosynthesis inhibitors, type 1, (17) Molting inhibitors, (18) Ecdysone (ecdysone) receptor agonists, (19) Octopamine receptor agonists, (20) Mitochondrial electron transport complex III inhibitors, (21) Mitochondrial electron transport complex I inhibitors (METI), (22) Voltage-dependent sodium channel blockers, (23) Acetyl CoA carboxylase inhibitors, (24) Mitochondrial electron transport complex IV inhibitors, (25) Mitochondrial electron transport complex III inhibitors, (28) Rianodine receptor modulators, (29) Chordal modulators with unidentified target site, (30) GABA-activated chloride (chloride) channel allosteric modulators, and (UN) agents with unknown or unclear mechanisms of action.

[0089] Specific examples of the above compound B are illustrated below.

[0090] (1A) Acetylcholinesterase (AChE) inhibitors (carbamates)

[0091] Alanycarb, Aldicarb, Bendiocarb, Benfuracarb, Butocarboxim, Butoxycarboxim, Carbaryl, Carbofuran, Carbosulfan, Ethiofencarb, Fenobucarb, Formetanate, Fumarate Furathiocarb, Isoprocarb, Methiocarb, Methomyl, Metolcarb, Oxamyl, Pirimicarb, Propoxur, Thiodicarb, Thiofanox, Triazamate, Trimethacarb, XMC, Xylylcarb.

[0092] Aldoxycarb, Allyxycarb, Aminocarb, Bufencarb, Cloethocarb, Fenothiocarb, Promecarb.

[0093] (1B) Acetylcholinesterase (AChE) inhibitors (organophosphates)

[0094] Acephate, Azamethiphos, Azinphos-ethyl, Azinphos-methyl, Cadusafos, Chlorethoxyfos, Chlorfenvinphos, Chlormephos, Chlorpyrifos, Chlorpyrifos-methyl, Coumaphos, Cyanophos, Demeton-S-methyl, Diazinon, Dichlorvos Lorvos / DDVP), Dicrotophos, Dimethoate, Dimethylvinphos, Disulfoton, EPN, Ethion, Ethoprophos, Famphur, Fenamiphos, Fenitrothion, Fenthion, Fosthiazate, Heptenophos, Imicyafos, Isofenphos, Isopropyl o-(methoxyaminothiophosphoryl) salicylateo-(methoxyaminothio-phosphoryl)salicylate), Isoxathion, Malathion, Mecarbam, Methamidophos, Methidathion, Mevinphos, Monocrotophos, Naled, Omethoate, Oxydemeton-methyl, Parathion, Parathion-methyl n-methyl), Phenthoate, Phorate, Phosalone, Phosmet, Phosphamidon, Phoxim, Pirimiphos-methyl, Profenofos, Propetamphos, Prothiofos, Pyraclofos, Pyridaphenthion, Quinalphos, Sulfotep ), Tebupirimfos, Temephos, Terbufos, Tetrachlorvinphos, Thiometon-methyl, Triazophos, Trichlorfon, Vamidothion, Bromophos-ethyl, Cyanofenphos, Demeton-S-methylsulfone, Dialifos, Dichlofe nthion), Dioxabenzofos, Etrimfos, Fensulfothion, Fonofos, Formothion, Iodofenphos, Isazofos, Isocarbofos, Methacrifos, Phosphocarb, Pirimiphos-ethyl, Propaphos, Prothoate, and Sulprofos.

[0095] (2) GABA-activated chloride channel blockers

[0096] Chlordane, Endosulfan, Ethiprole, Fipronil, Acetoprole, Camphechlor, Dienochlor, Heptachlor, Pyrafluprole, Pyriprole, and Flufiprole.

[0097] (3A) Sodium channel modulators (pyrethroids)

[0098] Acrinathrin, Allethrin, d-cis-transAllethrin, d-trans-Allethrin, Bifenthrin, Bioallethrin, Bioallethrin S-cyclopentenyl-isomer, Bioresmethrin, Cycloprothrin, Cyfluthrin thrin), beta-cyfluthrin (beta-Cyfluthrin), cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin , Cyphenothrin [(1R)-trans-isomers], Deltamethrin, Empenthrin [(EZ)-(1R)-isomers], Esfenvalerate, Etofenprox, Fenpropathrin, Fenvalerate, Flucythrinate, Flumethrin, τ-Flumethrin Tau-Fluvalinate, Halfenprox, Imiprothrin, Kadethrin, Permethrin, Phenothrin [(1R)-trans-isomer], Prallethrin, Pyrethrins, Resmethrin, Silafluofen, Tefluthrin, Tetramethrin,Tetramethrin [(1R)-isomers], Tralomethrin, Transfluthrin, kappa-Bifenthrin, Biopermethrin, Chloroprallethrin, Dimefluthrin, Fenfluthrin, Fenpirithrin, Flufenprox, Heptaflu ... Meperfluthrin), epsilon-Metofluthrin, Momfluorothrin, epsilon-Momfluorothrin, trans-Permethrin, Profluthrin, Protrifenbute, kappa-Tefluthrin, Terallethrin, Tetramethylfluthrin, Bioethanomethrin.

[0099] (3B) Sodium channel modulators (DDT class)

[0100] DDT, Methoxychlor.

[0101] (4) Competitive modulators of nicotinic acetylcholine receptors (nAChR)

[0102] Acetamiprid, Clothianidin, Dinotefuran, Imidacloprid, Nitenpyram, Thiacloprid, Thiamethoxam, Nicotine, Sulfoxaflor, Flupyradifurone, Triflumezopyrim, Nithiazine, Diclomezotiaz, N-[(E)-1-(6-chloro-3-pyridylmethyl)pyridine-2(1H)-ylidene]-2,2,2-trifluoroacetamide (Flupyrimin).

[0103] (5) Nicotinic acetylcholine receptor (nAChR) allosteric modulators

[0104] Spinetoram, Spinosad.

[0105] (6) Glutamate-activated chloride ion (chloride) channel (GluCl) allosteric modulator

[0106] Abamectin, Emamectin, Emamectin-benzoate, Lepimectin, Milbemectin, Doramectin, Eprinomectin, Ivermectin, Moxidectin, Selamectin.

[0107] (7) Juvenile hormone analogs

[0108] Hydroprene, Kinoprene, Methoprene; Fenoxycarb; Pyriproxifen, Diofenolan, Epofenonane, Triprene.

[0109] (8) Other nonspecific (multi-site) inhibitors

[0110] Methyl bromide, alkyl halides, chloropicrin, sodium aluminum fluoride, sulfuryl fluoride, borax, boric acid, disodium octaborate, sodium borate, sodium metaborate, tartar emetic, dazomet, metam, metam sodium, metam potassium.

[0111] (9) String organ TRPV channel modulator

[0112] Pymetrozine, Pyrifluquinazon, Afidopyropen.

[0113] (10) Mite growth inhibitors

[0114] Clofentezine, Diflovidazin, Hexythiazox, Etoxazole.

[0115] (11) Microbial-derived insect midgut lining destroyer

[0116] Bacillus thuringiensis subsp. israelensis, Bacillus thuringiensis subsp. aizawai, Bacillus thuringiensis subsp. kurstaki, Bacillus thuringiensis subsp. tenebrionis, Bt crop proteins: Cry1Ab, Cry1Ac, Cry1Fa, Cry1A.105, Cry2Ab, Vip3A, mCry3A, Cry3Ab, Cry3Bb, Cry34Ab1 / Cry35Ab1, Bacillus sphaericus.

[0117] (12) Mitochondrial ATP synthase inhibitors

[0118] Diafenthiuron, Azocyclotin, Cyhexatin, Fenbutatin-oxide, Propargite; Tetradifon.

[0119] (13) Oxidative phosphorylation uncouplers that disrupt the proton gradient

[0120] Chlorfenapyr, DNOC (4,6-dinitro-o-cresol), Sulfluramid, Binapacryl, Dinobuton, and Dinocap.

[0121] (14) Nicotinic acetylcholine receptor (nAChR) channel blockers

[0122] Bensultap, Cartap hydrochloride, Thiocyclam, Thiosultap-sodium.

[0123] (15) Chitin biosynthesis inhibitors, type 0

[0124] Bistrifluron, Chlorfluazuron, Diflubenzuron, Flucycloxuron, Flufenoxuron, Hexaflumuron, Lufenuron, Novaluron, Novifluron, Teflubenzuron, Triflumuron, Fluazuron.

[0125] (16) Chitin biosynthesis inhibitors, type 1

[0126] Buprofezin (Buprofezin).

[0127] (17) Molting inhibitors

[0128] Cyromazine.

[0129] (18) Ecdysone (ecdysone) receptor agonists

[0130] Chromafenozide, Halofenozide, Methoxyfenozide, Tebufenozide.

[0131] (19) Octopamine receptor agonists

[0132] Amitraz, Chlordimeform.

[0133] (20) Mitochondrial electron transport complex III inhibitors

[0134] Hydramethylnon, Acequinocyl, Fluacrypyrim, Bifenazate.

[0135] (21) Mitochondrial electron transport complex I inhibitor (METI)

[0136] Fenazaquin, Fenpyroximate, Pyridaben, Pyrimidifen, Tebufenpyrad, Tolfenpyrad, Rotenone.

[0137] (22) Potential-dependent sodium channel blockers

[0138] Indoxacarb, Metaflumizone.

[0139] (23) Acetyl CoA carboxylase inhibitors

[0140] Spirodiclofen, Spiromesifen, Spirotetramat, Spiropyridine ethyl ester.

[0141] (24) Mitochondrial electron transport complex IV inhibitors

[0142] Aluminum phosphide (Al-phosphide), calcium phosphide (Ca-phosphide), phosphine (Phosphine), zinc phosphide (Zn-phosphide); calcium cyanide (Ca-cyanide), sodium cyanide (Na-cyanide), potassium cyanide (K-cyanide).

[0143] (25) Mitochondrial electron transport complex II inhibitors

[0144] Cyenopyrafen, Cyflumetofen, Cyetpyrafen; Pyflubumide.

[0145] (28) Rianodine receptor modulators

[0146] Chlorantraniliprole, Cyantraniliprole, Cyclaniliprole, Flubendiamide, Cyhalodiamide, Tetrachlorantraniliprole, Tetraniliprole.

[0147] (29) The target site of the chord modulator has not been determined

[0148] Flonicamid.

[0149] (30) GABA-activated chloride ion (chloride ion) channel allosteric modulator

[0150] Broflanilide, 4-[(5RS)-5-(3,5-dichlorophenyl)-4,5-dihydro-5-trifluoromethyl-1,2-oxazol-3-yl]-N-[(EZ)-(methoxyimino)methyl]-o-toluamide, Isocycloseram; Afoxolaner, Fluralaner, Lotilaner, Sarolaner.

[0151] (UN) Azadirachtin, Benzoximate, Bromopropylate, Chinomethionat, Dicofol, Limesulfur, Mancozeb, Pyridalyl, Sulfur, Acynonapyr, Amidoflumet, Benzomate, Benzpyrimoxan, Chlorobenzilate, Dicyclanil, fenoxacrim, fentrifanil, flometoquin, flubenzimine, flufenzine, fluhexafon, fluopyram, metoxadiazone, 2-[3-(ethylsulfonyl)-2-pyridinyl]-5-[(trifluoromethyl)sulfonyl]benzoxazole (oxazosulfyl), Tetrasul, triarathene, tyclopyrazoflor, and dimpropyridaz.

[0152] In one embodiment, the insecticidal composition comprises a biologically effective amount of the isoxazoline-substituted benzamide compound (e.g., a compound of Formula I, Formula I' and Formula I") (component A), and at least one other active ingredient (component B) selected from the following compounds: chlorantraniliprole, spinetoram, lambda cyhalothrin, emamectin benzoate, abamectin, indoxacarb, lufenuron, chlorfenapyr, spirotetramat, trifluanid, diafenthiuron, ethoxaclofentil, acephate, bifenthrin, methoxyfenozide, spiromesifen, fipronil, methoxyfenop-ethyl, buprofezin, pymetrozine, clothianidin, nitenpyram, acetamiprid, dimethoprim, cyanamide, dinotefuran, ethiprole, imidacloprid, sulfoxaflor, thiamethoxam, tolfenpyrad or anthracene.

[0153] In another specific embodiment, the weight ratio of the active ingredients A and B in the insecticidal composition is 1:5000-10:1, 1:4000-1:1, 1:3000-1:5, 1:2000-1:10, 1:1000-1:20, 1:800-1:30, 1:600-1:50, 1:500-1:80 or 1:200-1:100.

[0154] The term "biologically effective amount" refers to an amount of a biologically active compound (e.g., a compound of Formula I, Formula I', and Formula I") that is sufficient to produce the desired biological effect when applied to (i.e., contacted with) the pest to be controlled or its environment, or the plant, the seed from which the plant grows, or the locus of the plant (e.g., the growth medium), thereby protecting the plant from damage by the pest or achieving other desired effects (e.g., increasing plant vigor). The compounds of the present invention can also be applied prophylactically to locations where pests or parasites are expected to appear.

[0155] Compound I, its stereoisomers and salts can be converted into conventional types of agrochemical compositions, such as solutions, emulsions, suspensions, dusts, powders, pastes, granules, pressed articles, capsules and mixtures thereof. Examples of composition types are suspensions (e.g. SC, OD, FS), emulsifiable concentrates (e.g. EC), emulsions (e.g. EW, EO, ES, ME), capsules (e.g. CS, ZC), pastes, pastilles, wettable powders or dusts (e.g. WP, SP, WS, DP, DS), pressed articles (e.g. BR, TB, DT), granules (e.g. WG, SG, GR, FG, GG, MG), insecticide preparations (e.g. LN) and gel formulations for treating plant propagation materials such as seeds (e.g. GF).

[0156] Suitable auxiliaries are solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, wetting agents, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesives, thickeners, humectants, repellents, attractants, feeding stimulants, compatibilizers, bactericides, antifreeze agents, defoamers, colorants, tackifiers and adhesives.

[0157] Suitable solvents and liquid carriers are water and organic solvents, such as medium to high boiling point mineral oil fractions, for example kerosene, diesel; oils of vegetable or animal origin; aliphatic, cyclic and aromatic hydrocarbons, for example toluene, paraffin, tetralin, alkylated naphthalenes; alcohols, for example ethanol, propanol, butanol, benzyl alcohol, cyclohexanol; glycols; DMSO; ketones, for example cyclohexanone; esters, for example lactates, carbonates, fatty acid esters, gamma-butyrolactone; fatty acids; phosphonates; amines; amides, for example N-methylpyrrolidone, fatty acid dimethylamides; and mixtures thereof.

[0158] Suitable solid carriers or fillers are mineral earths, for example silicates, silica gel, talc, kaolin, limestone, lime, chalk, clay, dolomite, diatomaceous earth, bentonite, calcium sulfate, magnesium sulfate, magnesium oxide; polysaccharides, for example cellulose, starch; fertilizers, for example ammonium sulfate, ammonium phosphate, ammonium nitrate, ureas; products of plant origin, for example cereal flour, bark flour, wood flour and nut shell flour, and mixtures thereof.

[0159] Suitable surfactants are surface-active compounds such as anionic, cationic, nonionic and amphoteric surfactants, block polymers, polyelectrolytes, and mixtures thereof. Such surfactants can be used as emulsifiers, dispersants, solubilizers, wetting agents, penetration enhancers, protective colloids or adjuvants.

[0160] Suitable anionic surfactants are alkali metals, alkaline earth metals or ammonium salts of sulfonic acid, sulfuric acid, phosphoric acid, carboxylic acids and mixtures thereof. Examples of sulfonates are alkylarylsulfonates, diphenylsulfonates, α-olefinsulfonates, ligninsulfonates, fatty acids and oily sulfonates, ethoxylated alkylphenol sulfonates, alkoxylated arylphenol sulfonates, condensed naphthalene sulfonates, dodecyl- and tridecylbenzene sulfonates, naphthalene and alkylnaphthalene sulfonates, sulfosuccinates or sulfosuccinamates. Examples of sulfates are sulfates of fatty acids and oily sulfates, ethoxylated alkylphenol sulfates, sulfates of alcohols, sulfates of ethoxylated alcohols or sulfates of fatty acid esters. Examples of phosphates are phosphate esters. Examples of carboxylates are alkylcarboxylates and carboxylated alcohols or alkylphenol ethoxylates.

[0161] Suitable nonionic surfactants are alkoxylates, N-substituted fatty acid amides, amine oxides, esters, sugar-based surfactants, polymeric surfactants and mixtures thereof. Examples of alkoxylates are compounds such as alcohols, alkylphenols, amines, amides, arylphenols, fatty acids or fatty acid esters that have been alkoxylated with 1-50 equivalents. Ethylene oxide and / or propylene oxide can be used for the alkoxylation, with ethylene oxide being preferred. Examples of N-substituted fatty acid amides are fatty acid glucamides or fatty acid alkanolamides. Examples of esters are fatty acid esters, glycerides or monoglycerides. Examples of sugar-based surfactants are sorbitan, ethoxylated sorbitan, sucrose and glucose esters or alkyl polyglucosides. Examples of polymeric surfactants are homopolymers or copolymers of vinyl pyrrolidone, vinyl alcohol or vinyl acetate.

[0162] Suitable cationic surfactants are quaternary surfactants, for example quaternary ammonium compounds with 1 or 2 hydrophobic groups, or salts of long-chain primary amines. Suitable amphoteric surfactants are alkyl betaines and imidazolines. Suitable block polymers are AB or ABA type block polymers comprising blocks of polyoxyethylene and polyoxypropylene, or ABC type block polymers comprising alkanol, polyoxyethylene and polyoxypropylene. Suitable polyelectrolytes are polyacids or polyalkalis. Examples of polyacids are alkali metal salts of polyacrylic acid or polyacid comb polymers. Examples of polyalkalis are polyvinylamine or polyvinylamine.

[0163] Suitable adjuvants are compounds which themselves have negligible or even no pesticidal activity and which improve the biological properties of the compounds I towards the target substances. Examples are surfactants, mineral or vegetable oils and other adjuvants.

[0164] Suitable thickeners are polysaccharides (eg xanthan gum, carboxymethylcellulose), inorganic clays (organically modified or unmodified), polycarboxylates and silicates.

[0165] Suitable fungicides are bronopol and isothiazolinone derivatives such as alkylisothiazolinones and benzisothiazolinones.

[0166] Suitable antifreeze agents are ethylene glycol, propylene glycol, urea and glycerol.

[0167] Suitable defoamers are silicones, long-chain alcohols and fatty acid salts.

[0168] Suitable colorants (for example red, blue or green) are low water-soluble pigments and water-soluble dyes. Examples are inorganic colorants (for example iron oxide, titanium oxide, iron hexacyanoferrate) and organic colorants (for example alizarin colorants, azo colorants and phthalocyanine colorants).

[0169] Suitable tackifiers or adhesives are polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol, polyacrylates, bio- or synthetic waxes and cellulose ethers.

[0170] The present invention also provides a method for controlling pests, which comprises contacting the pests or their environment with a biologically effective amount of the isoxazoline-substituted benzamide compound, its stereoisomers and agriculturally or veterinarily acceptable salts or the composition.

[0171] In one embodiment, the pest, its food supply, its habitat or its breeding ground, or the cultivated plants, plant propagation materials (such as seeds), soil, area, material or environment in which the pest grows or may grow, or the material, cultivated plants, plant propagation materials (such as seeds), soil, surface or space to be protected from infestation or infestation by the pest, is treated with a biologically effective amount of a compound of the invention or a composition as defined above.

[0172] The present invention also relates to the use of the compounds according to the invention, their stereoisomers and / or their agriculturally or veterinarily acceptable salts for combating pests.

[0173] The term "controlling pests" refers to inhibiting the development of pests (including mortality, reduced feeding, and / or mating disruption), and related expressions may be defined similarly.

[0174] The term "plant propagation material" should be construed as representing all propagation parts of a plant such as seeds, and asexual plant materials such as cuttings and tubers (e.g., potatoes) that can be used for propagating plants. This includes seeds, roots, fruits, tubers, bulbs, underground stems, branches, buds and other plant parts, including rice seedlings and seedlings transplanted by soil after germination or after emergence. Plant propagation material can be treated with plant protection compounds preventatively when or before planting or transplanting. The seedling can also be protected by the complete or partial treatment via dipping or watering before transplanting.

[0175] The term "plants" includes any type of plants, including "non-cultivated plants" and especially "cultivated plants".

[0176] The term "non-cultivated plant" refers to any wild-type variety or related variety or related genus of a cultivated plant.

[0177] The term "cultivated plants" is understood to include plants that have been modified by breeding, mutagenesis or genetic engineering, including but not limited to agricultural biotechnology products that are marketed or in development (see http: / / www.bio.org / speeches / pubs / er / agri_products.asp). Genetically modified plants are plants whose genetic material is not readily obtained by hybridization, mutation or natural recombination under natural conditions. One or more genes are typically integrated into the genetic material of a genetically modified plant to improve certain properties of the plant. Such genetic modifications also include but are not limited to targeted post-translational modifications of proteins, oligopeptides or polypeptides, for example by glycosylation or polymer addition such as prenylated, acetylated or farnesylated moieties or PEG moieties. DETAILED DESCRIPTION

[0178] The following examples are provided to illustrate the present invention and should not be considered to limit the present invention in any way. The scope of the rights claimed in the present invention is described in the claims.

[0179] Given the economical efficiency and diversity of the compounds, we have selected and synthesized a number of compounds. A selection of these compounds is listed in Table 1 below. The specific compound structures and corresponding compound information are shown in Table 1. The compounds in Table 1 are intended to better illustrate the present invention but are not intended to limit the present invention. Those skilled in the art should not interpret this as limiting the scope of the present invention to the following compounds.

[0180] Table 1 Compound structures and their 1 H NMR values

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189]

[0190]

[0191]

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199] Table A is constructed in the same manner as Table 1 above, except that the general formula I is replaced by the general formula I′ having a chiral center. (i.e., Q and Q1 are different), and in Table A, the entries under the "Serial Number" column heading are sequentially recited as 1(2R)-190(2R). For example, 1(2R) corresponds to a compound in Table 1 in which the 2 position of compound 1 is in the R configuration.

[0200] Table B is constructed in the same manner as Table 1 above, except that the compound having the general formula I is replaced with the compound having the general formula I having a chiral center. (i.e., Q and Q1 are different), and in Table B, the entries under the "Serial Number" column are sequentially recited as 1(5S,2R)-190(5S,2R). For example, 1(5S,2R) corresponds to a compound in Table 1 in which the 5-position is S-configured and the 2-position is R-configured.

[0201] Several methods for preparing the compounds of the present invention are described in detail in the following schemes and examples. The starting materials can be purchased commercially or can be prepared by methods known in the literature or as described in detail. It will be understood by those skilled in the art that other synthetic routes can also be used to synthesize the compounds of the present invention. Although the specific starting materials and conditions in the synthetic routes have been described below, they can be easily replaced with other similar starting materials and conditions, and these modifications or variations of the preparation methods of the present invention that result in various isomerizations of the compounds are included within the scope of the present invention. In addition, the preparation methods described below can be further modified according to the present disclosure using conventional chemical methods well known to those skilled in the art. For example, appropriate groups can be protected during the reaction, etc.

[0202] The following process examples are provided to facilitate a further understanding of the preparation methods of the present invention. The specific substances, types, and conditions used are intended to further illustrate the present invention and are not intended to limit its reasonable scope. The reagents used in the synthesis of the compounds shown in the table below are either commercially available or can be readily prepared by one of ordinary skill in the art.

[0203] Examples of representative compounds are shown below. The synthesis methods of other compounds are similar and will not be described in detail here.

[0204] 1. Synthesis of compound 3(5S,2R)

[0205] (1) A 50 ml round-bottom flask was added with 10 ml of DCM, 3-1 (0.3 g, 1 eq), D-alanine methyl ester hydrochloride (0.35 g, 1.5 eq), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 0.64 g, 2 eq), and 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 1.28 g, 2 eq). The mixture was reacted at 45°C for 16 h. After the reaction was complete, the solvent was removed by concentration under reduced pressure, and the product 3-2 (367 mg, 82% yield) was obtained by silica gel column chromatography as a white solid.

[0206]

[0207] (2) A 50 ml round-bottom flask was charged with 10 ml of dichloroethane, 3-2 (0.15 g, 1 eq), 3-3 (0.18 g, 1 eq), potassium carbonate (0.09 g, 1.2 eq), and triethylamine (0.07 g, 1.2 eq). The temperature was raised to 80°C and the reaction was continued for 16 h. After the reaction was complete, the solvent was removed by concentration under reduced pressure. Silica gel column chromatography afforded the product 3-4 (156 mg, 49% yield) as a white solid.

[0208]

[0209] (3) A 50 ml round-bottom flask was charged with 10 ml of DCM and 3-4 (0.15, 1 eq). The catalyst (35 mg) was added at 0°C and stirred evenly. 0.06 g (6 eq) of sodium hydroxide was dissolved in 5 volumes of water, and hydroxylamine hydrochloride (0.09 g, 5 eq, containing 50% water) was added. The mixture was stirred for 30 minutes. The resulting mixture was slowly added dropwise to the reaction system and reacted at 0°C for 2 hours. After the reaction was complete, the mixture was extracted with DCM, and the organic layer was concentrated under reduced pressure to remove the solvent. The product 3(5S,2R) was obtained as a white solid (82 mg, purity 97%, ee 53, yield 53%) by silica gel column chromatography.

[0210]

[0211] 2. Synthesis of compound 3(2R)

[0212] 3-5 (1 g, 1 eq) was dissolved in 25 ml of DCM, and D-alanine methyl ester hydrochloride (574.17 mg, 2 eq), HOBT (416.89 mg, 1.5 eq) and triethylamine (312.20 mg, 1.5 eq) were added in sequence. The mixture was stirred for 5 minutes, and then EDCI (591.44 mg, 1.5 eq) was added. The reaction was allowed to react at room temperature for 3 h. After the reaction was complete, water was added to the system for extraction. The aqueous layer was extracted twice with DCM, and the organic phase was washed 3-5 times with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The white solid product 3(2R) (800 mg, purity 95%, yield 68%) was obtained by forward purification.

[0213]

[0214] 3. Synthesis of compound 151(2R)

[0215] 3(2R) (0.5 g, 0.87 mmol) was dissolved in 20 ml of THF, and a solution of LiOH (83.83 mg, 4 eq, 3.5 mmol) in water (5 ml) was added dropwise under ice bath. The reaction was allowed to react at room temperature for 12 h. After the reaction was completed as detected by LCMS, the product was concentrated under reduced pressure to remove THF, and 2 M dilute hydrochloric acid was added to adjust the pH to 4. EA was added for extraction, and the organic phase was concentrated under reduced pressure. Purification with normal phase gave 151(2R) (400 mg, 82% yield, 95% purity).

[0216]

[0217] 4. Synthesis of compound 4(2R)

[0218] 151(2R) (100 mg, 1 eq) was dissolved in 5 mL of DMF, and cesium carbonate (175 mg, 3 eq) and iodomethane (128 mg, 5 eq) were added sequentially with stirring. The temperature was raised to 45 degrees and the reaction was allowed to proceed for 12 h. After the reaction was completed as detected by LCMS, water was added to the reaction solution and extracted with ethyl acetate. The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure and purified by normal phase to give 4(2R) (90 mg, 86% yield, 96% purity).

[0219]

[0220] 5. Synthesis of compound 30(2R)

[0221] 151(2R) (0.15 g, 269.17 umol) was dissolved in 10 mL of DMF, and iodoethane (62.97 mg, 1.5 eq, 403.75 umol) and potassium carbonate (111.60 mg, 3 eq, 807.51 umol) were added. The reaction was carried out at room temperature for 6 h. LCMS detected that the reaction was complete. The reaction solution was extracted with water and EA, and the aqueous phase was extracted twice with EA. The organic phases were combined and washed three times with saturated sodium chloride solution. The organic phase was concentrated under reduced pressure and purified by forward purification to obtain 30(2R) (100 mg, 63% yield, 95% purity).

[0222]

[0223] 6. Synthesis of Compound 80(2R)

[0224] A 50ml round-bottom flask was charged with 15ml of DCM solvent, the acid compound 151(2R) (0.18g, 1eq), acetone oxime (0.04g, 1.5eq), EDCI (0.09g, 1.5eq), and HOBT (0.07g, 1.5eq). The atmosphere was replaced with nitrogen and stirred at room temperature for 1h. After completion of the reaction, the mixture was extracted three times with dichloromethane and water. The organic phase was concentrated under reduced pressure to remove the solvent, and normal phase separation afforded the product 80(2R) (120mg, 61%) as a white solid.

[0225]

[0226] 7. Synthesis of compound 154(2R)

[0227] 154-1 (800 mg, 1.0 eq) was added to EtOH, and NH2OH.HCl (340 mg, 1.1 eq) was added dropwise at 0°C. After the addition was complete, the mixture was reacted at room temperature for 1 hour. After the intermediate control reaction was complete, the solvent was removed by concentration under reduced pressure. Water was added to the reaction solution, and the mixture was extracted twice with EA. The organic phase was washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product 154-2 (740 mg), which was used directly in the next step.

[0228]

[0229] 154-2 (740 mg, 1 eq) was dissolved in 10 ml of DMF, the temperature was raised to 35 degrees, NCS (560 mg, 1.1 eq) was added, and the reaction was carried out for 1.5 h. After the mid-control reaction was completed, it was cooled to room temperature, water and EA were added, and the mixture was extracted twice with EA. The organic phase was washed twice with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product of 154-3 (850 mg), which was used directly in the next step.

[0230]

[0231] 154-3 (850 mg, 1 eq) was dissolved in 10 ml of DCM, triethylamine (750 mg, 2 eq) was added under ice bath, and a (1.15 g, 1 eq) was added dropwise. After the addition was complete, the mixture was reacted for 2 h. After the mid-control reaction was complete, water and DCM were added for extraction. The organic phase was purified by normal phase to obtain 154-4 (480 mg).

[0232]

[0233] 154-4 (480 mg, 1 eq) was dissolved in 20 ml of THF, and an aqueous solution of NaOH (154 mg, 4 eq) was added dropwise under ice bath. The temperature was raised to 60 degrees and the reaction was carried out for 4 h. After the intermediate control reaction was completed, the reaction was cooled to room temperature and 2 M dilute hydrochloric acid was added to adjust the pH to 4. EA was added for extraction, and the organic phase was concentrated under reduced pressure to obtain 154-5 (400 mg).

[0234]

[0235] 154-5 (100 mg, 1 eq) was dissolved in 10 mL of DCM, and D-alanine methyl ester hydrochloride (42 mg, 1.5 eq), HOBT (41 mg, 1.5 eq) and triethylamine (41 mg, 2 eq) were added in sequence. The mixture was stirred at room temperature for 5 min, and finally EDCI (59 mg, 1.5 eq) was added. The reaction was allowed to proceed at room temperature for 0.5 h. After the intermediate control reaction was completed, water and DCM were added for extraction. The aqueous phase was extracted twice with DCM, and the organic phases were combined. The organic phases were washed three times with saturated sodium chloride solution. The organic phase was concentrated under reduced pressure and purified forward to obtain 154(2R) (60 mg).

[0236]

[0237] 8. Synthesis of compound 144(2R)

[0238] 144-1 (1.15 g, 1.0 eq) was added to 50 ml of DMF, and NCS (1.05 eq) was added dropwise to the reaction solution at 35°C. After reacting for 1 hour, LCMS detected that the raw material disappeared and the main peak was the product peak. EA and water were added for extraction, and the reaction solution was extracted with ethyl acetate and washed with saturated brine (100 ml*3). The organic phase was concentrated to obtain a crude product 144-2 (1.1 g), which was directly used in the next step.

[0239]

[0240] At 0°C, a (1.2 eq) was dissolved in DCM, and triethylamine (2 eq) was added dropwise. After the addition was complete, 144-2 (0.2 g, 1 eq) was added dropwise. The temperature was raised to 40°C and stirred overnight. LCMS showed the presence of the product. The mixture was washed with saturated brine (150 ml*3) and extracted with EA to obtain an oily substance. 144-3 (0.23 g, 54.0% yield) was obtained by column chromatography.

[0241]

[0242] To a mixed solvent of 12 ml THF and 4 ml water, 144-3 (0.23 g, 1 eq) was added. Sodium hydroxide (3 eq) was added in batches with stirring at room temperature. The temperature was raised to 40°C and stirred overnight. The product was detected by LCMS. The solvent was concentrated, and hydrochloric acid was added to adjust the pH to acidic. Ethyl acetate was added for extraction. The organic phase was concentrated to obtain 144-4 (0.2 g, 89% yield).

[0243]

[0244] To a 100 mL single-necked flask was added 144-4 (100 mg, 1.0 eq), D-alanine methyl ester hydrochloride (1.1 eq), 8 mL of dichloromethane, triethylamine (2.0 eq), and HOBT (1.5 eq). The mixture was stirred on ice for 5 min, EDCI (1.5 eq) was added, and stirring continued for 1 h. LCMS analysis showed that the starting material was almost completely consumed, with a major new peak generated and a correct MS signal. The reaction mixture was added with 20 mL of water and subjected to separation extraction three times. The combined organic phases were washed three times with saturated brine, dried over anhydrous sodium sulfate, and purified by column chromatography to yield 144(2R) (90 mg, 76.7% yield) as a white solid.

[0245]

[0246] Biological activity evaluation:

[0247] (1) Insecticidal activity test:

[0248] The compound of the present invention was dissolved in acetone and then diluted with water to form a gradient of different concentrations (ppm). Corn leaves were immersed in the solutions of varying concentrations for approximately 20 seconds, air-dried, and placed in Petri dishes. Third-instar fall armyworms were introduced into each dish. Cabbage leaves were immersed in the solutions of varying concentrations for approximately 20 seconds, air-dried, and placed in Petri dishes. Third-instar beet armyworms were introduced into each dish. Peanut leaves were immersed in the solutions of varying concentrations for approximately 20 seconds, air-dried, and placed in Petri dishes. Adult spider mites and adult peanut aphids were introduced into each dish. Zizania latifolia leaves were immersed in the solutions of varying concentrations for approximately 20 seconds, air-dried, and placed in Petri dishes. Fourth-instar striped stem borers were introduced into each dish. Ten insects were placed in each Petri dish, covered, and stored in a constant temperature chamber at 25°C. After 48 hours, the number of dead insects was examined, and the mortality rate was calculated using the formula: mortality rate (%) = (number of dead insects / number of test insects) * 100. The experiment was conducted in duplicate.

[0249] Table 2 Insecticidal test results

[0250]

[0251] Note: N stands for no data; Reference compound A: (From patent WO2005 / 085216).

[0252] (2) Composition insecticide activity determination test:

[0253] 2.1) Test conditions and operating steps

[0254] Test targets: Fall armyworm (3rd instar), cotton aphid (adult)

[0255] Referring to the above insecticidal activity test, when the test target is cotton aphid, the leaves are selected from zucchini leaves.

[0256] 2.2) Qualitative evaluation of efficiency

[0257] Toxicity tests were performed at different ratios within the selected range, and the optimal ratio was selected based on the synergistic effect. A synergistic effect > 0 indicates a synergistic effect; a synergistic effect close to 0 indicates an additive effect; and a synergistic effect < 0 indicates an antagonistic effect.

[0258] Synergistic effect = actual mortality rate - theoretical mortality rate

[0259] Theoretical mortality rate = 1-(1-P1)(1-P2)

[0260] Where, P1, P2 are the mortality rates of each single dose in the mixture.

[0261] Table 3 Qualitative evaluation test results of the composition synergistic effect

[0262]

[0263]

[0264] At the same time, after many tests, it was found that many of the compounds and compositions of the present invention have good control activity against agricultural pests such as Lepidoptera (such as corn borer, striped stem borer, diamondback moth, Spodoptera litura, beet armyworm, cotton bollworm, fall armyworm, armyworm, etc.), Homoptera (such as cotton aphid, radish aphid, pea aphid, peanut aphid, green stink bug, etc.), Acarina (such as two-spotted spider mite, truncate spider mite, Turkestan spider mite, etc.), Diptera (such as leek bradgy fungus gnat, etc.), Coleoptera (such as yellow flea beetle, monkey leaf beetle, etc.) and thrips (such as palm thrips, onion thrips, tobacco thrips, etc.), as well as sanitary pests such as cockroaches (such as termites, cockroaches, etc.) and Muscidae (such as flies, mosquitoes, etc.). They not only have the characteristics of broad spectrum, high efficiency, and strong systemic absorption, but can also effectively control resistant pests and have certain commercial value.

Claims

1. An isoxazoline-substituted benzamide compound as shown in Formula I, its stereoisomers and agriculturally or veterinarily acceptable salts: in, X represents hydrogen, halogen, alkoxy or alkylthio; Y represents halogen or halogenated alkyl; Z, Z1 each independently represent hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl or cyano; P and P1 independently represent CH or N; Q and Q1 independently represent hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, cyanoalkyl, hydroxyalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkylthio, alkylamino, haloalkoxy, haloalkylthio, alkylcarbonyl, alkoxycarbonyl, alkoxyalkyl, haloalkoxyalkyl, alkylaminoalkyl, aryl, heterocyclyl, arylalkyl or heterocyclylalkyl, wherein the "alkyl", "alkenyl" or "alkynyl" independently represent unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(CO)N(R1)2, -(SO2)R1 or -N(R1)2. wherein the “cycloalkyl”, “cycloalkylalkyl”, “aryl”, “heterocyclyl”, “arylalkyl” or “heterocyclylalkyl” are independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; M represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic, aryl, Wherein, the "alkyl", "alkenyl" or "alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, cycloalkyl, trialkylsilyl, cycloalkenyl, heterocyclyl, aryl, wherein the “cycloalkyl”, “cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; R represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclic, aryl, Wherein, the "alkyl", "alkenyl" or "alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, cycloalkyl, trialkylsilyl, cycloalkenyl, heterocyclyl, aryl, wherein the “cycloalkyl”, “cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; X 11 Each of the following groups independently represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heterocyclyl, heterocyclylalkyl, aryl or arylalkyl, wherein the "alkyl", "alkenyl" or "alkynyl" are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the "cycloalkyl", "cycloalkylalkyl", "cycloalkenyl", "cycloalkenylalkyl", "heterocyclyl", "heterocyclylalkyl", "aryl" or "arylalkyl" are independently substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2. " or "arylalkyl" are each independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; X 12 Each of the following independently represents an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkylalkyl group, a cycloalkenyl group, a cycloalkenylalkyl group, a heterocyclyl group, a heterocyclylalkyl group, an aryl group or an arylalkyl group, wherein the "alkyl group", "alkenyl group" or "alkynyl group" are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the "cycloalkyl group", "cycloalkylalkyl group", "cycloalkenyl group", "cycloalkenylalkyl group", "heterocyclyl group", "heterocyclylalkyl group", "aryl group" or "arylalkyl group" are independently substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2. or "arylalkyl" is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; X 13 、X 14 Each independently represents hydrogen, halogen, cyano, alkoxy, alkoxyalkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulfonyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, or a group CX 13 X 14 Together they form an unsubstituted or substituted ring structure, or the group NX 13 X 14 Together they form an unsubstituted or substituted heterocyclic group with a nitrogen atom at the 1-position, wherein the "alkyl", "alkenyl" or "alkynyl" are independently unsubstituted or substituted with at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the "cycloalkyl", "cycloalkylalkyl", "cycloalkenyl", "cycloalkenylalkyl", "aryl", "arylalkyl", "heterocyclyl" or "heterocyclylalkyl" are independently unsubstituted. or substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, halocycloalkyl, cycloalkyl substituted by alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-alkyl-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; R1 independently represents hydrogen, alkyl, haloalkyl, phenyl or phenyl substituted by at least one group selected from halogen, cyano, nitro, alkyl, haloalkyl, alkoxycarbonyl, alkylthio, alkylsulfonyl, alkoxy or haloalkoxy.

2. The isoxazoline-substituted benzamide compound, its stereoisomers and agriculturally or veterinarily acceptable salts according to claim 1, characterized in that: X represents hydrogen, halogen, C1-C8 alkoxy or C1-C8 alkylthio; Y represents halogen or halogenated C1-C8 alkyl; Z and Z1 independently represent hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halogenated C1-C8 alkyl or cyano; Q and Q1 each independently represent hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, cyano C1-C8 alkyl, hydroxy C1-C8 alkyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C8 alkyl, C1-C8 alkoxy, C1-C8 alkylthio, C1-C8 alkylamino, halogenated C1-C8 alkoxy, halogenated C1-C8 alkylthio, C1-C8 alkylcarbonyl, C1-C8 alkoxycarbonyl, C1-C8 alkoxy C1-C8 alkyl, halogenated C1-C8 alkoxy C1-C8 alkyl, C1-C8 alkylamino C1-C8 alkyl, aryl, heterocyclic group, aryl C1-C8 alkyl or heterocyclic C1-C8 alkyl, wherein, The "C1-C8 alkyl", "C2-C8 alkenyl" or "C2-C8 alkynyl" are each independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(CO)N(R1)2, -(SO2)R1 or -N(R1)2; the "C3-C8 cycloalkyl", "C3-C8 cycloalkylC1-C8 alkyl", "aryl", "heterocyclyl", "arylC1-C8 alkyl" or "heterocyclylC1-C8 alkyl" are each independently unsubstituted or substituted by at least one of oxo, halogen, cyano, nitro, C1-C8 Alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halogenated C1-C8 alkyl, halogenated C2-C8 alkenyl, halogenated C2-C8 alkynyl, halogenated C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by C1-C8 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a condensed ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; M represents hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, heterocyclic group, aryl, Wherein, the "C1-C8 alkyl", "C2-C8 alkenyl" or "C2-C8 alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, C3-C8 cycloalkyl, tri-C1-C8 alkylsilyl, C3-C8 cycloalkenyl, heterocyclyl, aryl, wherein the “C3-C8 cycloalkyl”, “C3-C8 cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo-C1-C8 alkyl, halo-C2-C8 alkenyl, halo-C2-C8 alkynyl, halo-C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by C1-C8 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; R represents hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, heterocyclic group, aryl, Wherein, the "C1-C8 alkyl", "C2-C8 alkenyl" or "C2-C8 alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, C3-C8 cycloalkyl, tri-C1-C8 alkylsilyl, C3-C8 cycloalkenyl, heterocyclyl, aryl, wherein the “C3-C8 cycloalkyl”, “C3-C8 cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo-C1-C8 alkyl, halo-C2-C8 alkenyl, halo-C2-C8 alkynyl, halo-C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by C1-C8 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; X 11 and C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C8 alkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkenylC1-C8 alkyl, heterocyclyl, heterocyclylC1-C8 alkyl, aryl or arylC1-C8 alkyl, wherein the "C1-C8 alkyl", "C2-C8 alkenyl" or "C2-C8 alkynyl" are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the "C3-C8 cycloalkyl", "C3-C8 cycloalkylC1-C8 alkyl", "C3-C8 cycloalkenyl", "C3-C8 cycloalkenylC1-C8 alkyl", " "Heterocyclyl", "heterocyclyl C1-C8 alkyl", "aryl" or "aryl C1-C8 alkyl" are each independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo-C1-C8 alkyl, halo-C2-C8 alkenyl, halo-C2-C8 alkynyl, halo-C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by C1-C8 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; X 12 and C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C8 alkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkenylC1-C8 alkyl, heterocyclyl, heterocyclylC1-C8 alkyl, aryl or arylC1-C8 alkyl, wherein the "C1-C8 alkyl", "C2-C8 alkenyl" or "C2-C8 alkynyl" are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the "C3-C8 cycloalkyl", "C3-C8 cycloalkylC1-C8 alkyl", "C3-C8 cycloalkenyl", "C3-C8 cycloalkenylC1-C8 alkyl", "heterocyclylC1-C8 alkyl", "heterocyclylC1-C8 alkyl", aryl or arylC1-C8 alkyl, wherein the "C1-C8 alkyl", "C2-C8 alkenyl" or "C2-C8 alkynyl" are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2. "Cycyl", "heterocyclyl C1-C8 alkyl", "aryl" or "aryl C1-C8 alkyl" are each independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo-C1-C8 alkyl, halo-C2-C8 alkenyl, halo-C2-C8 alkynyl, halo-C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by C1-C8 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; X 13 、X 14 Each independently represents hydrogen, halogen, cyano, C1-C8 alkoxy, C1-C8 alkoxyC1-C8 alkyl, C1-C8 alkylcarbonyl, C1-C8 alkoxycarbonyl, C1-C8 alkylsulfonyl, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkylC1-C8 alkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkenylC1-C8 alkyl, aryl, arylC1-C8 alkyl, heterocyclyl or heterocyclylC1-C8 alkyl, or the group CX 13 X 14 Together they form a 5- to 8-membered carbon ring or a heterocyclic ring containing oxygen, sulfur or nitrogen, or the group NX 13 X 14 Formed together wherein the “C1-C8 alkyl”, “C2-C8 alkenyl” or “C2-C8 alkynyl” are each independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2; and the “C3-C8 cycloalkyl”, “C3-C8 cycloalkylC1-C8 alkyl”, “C3-C8 cycloalkenyl”, “C3-C8 cycloalkenylC1-C8 alkyl”, “aryl”, “arylC1-C8 alkyl”, “heterocyclyl” or “heterocyclylC1-C8 alkyl” are each independently unsubstituted or substituted by at least one of oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo The 5- to 8-membered carbon ring or heterocyclic ring containing oxygen, sulfur or nitrogen is unsubstituted or substituted by at least one of C1-C8 alkyl, C2-C8 halogenated alkenyl, C2-C8 alkynyl, C3-C8 halogenated cycloalkyl, C3-C8 cycloalkyl substituted by C1-C8 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C8 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a condensed ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-, and the "5- to 8-membered carbon ring or heterocyclic ring containing oxygen, sulfur or nitrogen" is unsubstituted or substituted by at least one of C1-C8 alkyl, C1-C8 alkoxycarbonyl or benzyl, or forms a condensed ring structure with an aryl or heterocyclic group; is unsubstituted or substituted by at least one group selected from oxo, C1-C8 alkyl or C1-C8 alkoxycarbonyl; R1 independently represents hydrogen, C1-C8 alkyl, halogenated C1-C8 alkyl, phenyl or phenyl substituted by at least one group selected from halogen, cyano, nitro, C1-C8 alkyl, halogenated C1-C8 alkyl, C1-C8 alkoxycarbonyl, C1-C8 alkylthio, C1-C8 alkylsulfonyl, C1-C8 alkoxy or halogenated C1-C8 alkoxy.

3. The isoxazoline-substituted benzamide compound, its stereoisomers and agriculturally or veterinarily acceptable salts according to claim 1 or 2, characterized in that: X represents hydrogen, halogen, C1-C6 alkoxy or C1-C6 alkylthio; Y represents halogen or halogenated C1-C6 alkyl; Z and Z1 independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halogenated C1-C6 alkyl or cyano; Q and Q1 each independently represent hydrogen, halogen, hydroxy, cyano, amino, nitro, formyl, cyano C1-C6 alkyl, hydroxy C1-C6 alkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkylamino, halogenated C1-C6 alkoxy, halogenated C1-C6 alkylthio, C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, C1-C6 alkoxy C1-C6 alkyl, halogenated C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkylamino C1-C6 alkyl, aryl, heterocyclic group, aryl C1-C6 alkyl or heterocyclic C1-C6 alkyl, wherein, The "C1-C6 alkyl", "C2-C6 alkenyl" or "C2-C6 alkynyl" are each independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(CO)N(R1)2, -(SO2)R1 or -N(R1)2; the "C3-C6 cycloalkyl", "C3-C6 cycloalkylC1-C6 alkyl", "aryl", "heterocyclyl", "arylC1-C6 alkyl" or "heterocyclylC1-C6 alkyl" are each independently unsubstituted or substituted by at least one of oxo, halogen, cyano, nitro, C1-C6 Alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halogenated C1-C6 alkyl, halogenated C2-C6 alkenyl, halogenated C2-C6 alkynyl, halogenated C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted by C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a condensed ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; M represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, heterocyclic group, aryl, Wherein, the "C1-C6 alkyl", "C2-C6 alkenyl" or "C2-C6 alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, C3-C6 cycloalkyl, tri-C1-C6 alkylsilyl, C3-C6 cycloalkenyl, heterocyclyl, aryl, wherein the “C3-C6 cycloalkyl”, “C3-C6 cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo-C1-C6 alkyl, halo-C2-C6 alkenyl, halo-C2-C6 alkynyl, halo-C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted by C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; R represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkenyl, heterocyclic group, aryl, Wherein, the "C1-C6 alkyl", "C2-C6 alkenyl" or "C2-C6 alkynyl" are independently unsubstituted or selected from halogen, cyano, nitro, C3-C6 cycloalkyl, tri-C1-C6 alkylsilyl, C3-C6 cycloalkenyl, heterocyclyl, aryl, wherein the “C3-C6 cycloalkyl”, “C3-C6 cycloalkenyl”, “heterocyclyl” or “aryl” is independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo-C1-C6 alkyl, halo-C2-C6 alkenyl, halo-C2-C6 alkynyl, halo-C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted by C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; X 11 and C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C6 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylC1-C6 alkyl, heterocyclyl, heterocyclylC1-C6 alkyl, aryl or arylC1-C6 alkyl, wherein the "C1-C6 alkyl", "C2-C6 alkenyl" or "C2-C6 alkynyl" are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the "C3-C6 cycloalkyl", "C3-C6 cycloalkylC1-C6 alkyl", "C3-C6 cycloalkenyl", "C3-C6 cycloalkenylC1-C6 alkyl", " "Heterocyclyl", "heterocyclyl C1-C6 alkyl", "aryl" or "aryl C1-C6 alkyl" are each independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo-C1-C6 alkyl, halo-C2-C6 alkenyl, halo-C2-C6 alkynyl, halo-C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted by C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; X 12 and C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C6 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylC1-C6 alkyl, heterocyclyl, heterocyclylC1-C6 alkyl, aryl or arylC1-C6 alkyl, wherein the "C1-C6 alkyl", "C2-C6 alkenyl" or "C2-C6 alkynyl" are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the "C3-C6 cycloalkyl", "C3-C6 cycloalkylC1-C6 alkyl", "C3-C6 cycloalkenyl", "C3-C6 cycloalkenylC1-C6 alkyl", "heterocyclylC1-C6 alkyl", aryl or arylC1-C6 alkyl, wherein the "C1-C6 alkyl", "C2-C6 alkenyl" or "C2-C6 alkynyl" are independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2. "Cycyl", "heterocyclyl C1-C6 alkyl", "aryl" or "aryl C1-C6 alkyl" are each independently unsubstituted or substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo-C1-C6 alkyl, halo-C2-C6 alkenyl, halo-C2-C6 alkynyl, halo-C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted by C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a fused ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-; X 13 、X 14 Each independently represents hydrogen, halogen, cyano, C1-C6 alkoxy, C1-C6 alkoxyC1-C6 alkyl, C1-C6 alkylcarbonyl, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfonyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkylC1-C6 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenylC1-C6 alkyl, aryl, arylC1-C6 alkyl, heterocyclyl or heterocyclylC1-C6 alkyl, or the group CX 13 X 14 Together they form a 5- to 8-membered carbon ring or a heterocyclic ring containing oxygen, sulfur or nitrogen, or the group NX 13 X 14 Formed together Wherein, the "C1-C6 alkyl", "C2-C6 alkenyl" or "C2-C6 alkynyl" are each independently unsubstituted or substituted by at least one of halogen, -OR1, -SR1, -(CO)OR1, -(SO2)R1 or -N(R1)2, and the "C3-C6 cycloalkyl", "C3-C6 cycloalkylC1-C6 alkyl", "C3-C6 cycloalkenyl", "C3-C6 cycloalkenylC1-C6 alkyl", "aryl" , "aryl C1-C6 alkyl", "heterocyclyl" or "heterocyclyl C1-C6 alkyl" are each independently unsubstituted or selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo-substituted C1-C6 alkyl, halo-substituted C2-C6 alkenyl, halo-substituted C2-C6 alkynyl, halo-substituted C3-C6 cycloalkyl, C3-C6 cycloalkyl substituted by C1-C6 alkyl, -OR1, -SR1, -(CO)OR1, -(SO2)R1, -N(R1)2 or -O-(C1-C6 alkyl)-(CO)OR1, or two adjacent carbon atoms on the ring form a condensed ring with unsubstituted or halogen-substituted -OCH2CH2- or -OCH2O-, and the "5- to 8-membered carbon ring or heterocycle containing oxygen, sulfur or nitrogen" is unsubstituted or substituted with at least one group selected from C1-C6 alkyl, C1-C6 alkoxycarbonyl or benzyl, or forms a condensed ring structure with an aryl or heterocyclic group; is unsubstituted or substituted by at least one group selected from oxo, C1-C6 alkyl or C1-C6 alkoxycarbonyl; R1 each independently represents hydrogen, C1-C6 alkyl, halo-C1-C6 alkyl, phenyl or phenyl substituted by at least one group selected from halogen, cyano, nitro, C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkoxycarbonyl, C1-C6 alkylthio, C1-C6 alkylsulfonyl, C1-C6 alkoxy or halo-C1-C6 alkoxy; Preferably, X represents hydrogen, fluorine, chlorine, methoxy or methylthio; Y represents chlorine or fluorine; Z represents hydrogen, methyl, ethyl, isopropyl, chlorine, trifluoromethyl or vinyl; Z1 represents hydrogen or chlorine; Q represents hydrogen, methyl, isopropyl, cyclopropyl, methoxy, trifluoromethyl, benzyl, Q1 represents hydrogen; P represents CH or N; P1 represents CH or N; M represents hydrogen, methyl, ethyl, allyl, propargyl, R represents hydrogen or methyl.

4. An isoxazoline-substituted benzamide compound having a chiral center as shown in Formula I', its stereoisomers and agriculturally or veterinarily acceptable salts: in, The definitions of substituents X, Y, Z, Z1, P, P1, R, Q, Q1, and M are as shown in any one of claims 1 to 3; the carbon atom at position 2 is a chiral center and has a stereochemical purity of 60-100% (R) based on the content of stereoisomers with R and S configurations at this position, preferably 70-100% (R), more preferably 80-100% (R), further preferably 90-100% (R), and even more preferably 95-100% (R).

5. An isoxazoline-substituted benzamide compound having a chiral center as shown in Formula I", its stereoisomers and agriculturally or veterinarily acceptable salts: in, The definitions of substituents X, Y, Z, Z1, P, P1, R, Q, Q1, and M are as shown in any one of claims 1 to 3; Based on the content of stereoisomers having R and S configurations at position 5, it has a stereochemical purity of 60-100% (S), preferably 70-100% (S), more preferably 80-100% (S), further preferably 90-100% (S), and even more preferably 95-100% (S); The carbon atom at position 2 is a chiral center. Based on the content of stereoisomers with R and S configurations at this position, it has a stereochemical purity of 60-100% (R), preferably 70-100% (R), more preferably 80-100% (R), further preferably 90-100% (R), and even more preferably 95-100% (R).

6. The isoxazoline-substituted benzamide compound, its stereoisomers and agriculturally or veterinarily acceptable salts according to any one of claims 1 to 5, characterized in that: The compound is selected from any one of Table 1, Table A and Table B.

7. A method for preparing the isoxazoline-substituted benzamide compound, its stereoisomers and agriculturally or veterinarily acceptable salts according to any one of claims 1 to 6, comprising the following steps: The compound represented by general formula II is reacted with the compound represented by general formula III in the presence of a condensing agent to obtain a compound represented by general formula I. The chemical reaction equation is as follows: Wherein, the definitions of substituents X, Y, Z, Z1, P, P1, R, Q, Q1, and M are as described in any one of claims 1 to 6; preferably, the condensing agent is PyBOP, HATU, HOBt-EDCI, CDI, DCC, or DBU; and the reaction is carried out in the presence of a base and a solvent.

8. An insecticidal composition, characterized in that The invention comprises a biologically effective amount of at least one of the isoxazoline-substituted benzamide compound according to any one of claims 1 to 6, its stereoisomers and agriculturally or veterinarily acceptable salts; preferably, it also comprises a formulation adjuvant; more preferably, it also comprises other active ingredients, such as chlorantraniliprole, spinetoram, lambda cyhalothrin, emamectin benzoate, abamectin, indoxacarb, lufenuron, chlorfenapyr, spirotetramat, trifluanid, diafenthiuron, ethoxaclofentyl, acephate, bifenthrin, methoxyfenozide, spiromesifen, fipronil, methoxypiperidin, buprofezin, pymetrozine, clothianidin, nitenpyram, acetamiprid, diprofenapyr, cyanamide, dinotefuran, ethiprole, imidacloprid, sulfoxaflor, thiamethoxam, tolfenpyrad or anthracene.

9. A method for controlling pests, characterized in that: The method comprises contacting the pest or its environment with a biologically effective amount of the isoxazoline-substituted benzamide compound according to any one of claims 1 to 6, its stereoisomers and agriculturally or veterinarily acceptable salts, or the composition according to claim 8.

10. Use of the isoxazoline-substituted benzamide compound according to any one of claims 1 to 6, its stereoisomers and agriculturally or veterinarily acceptable salts in controlling pests.